lapatinib has been researched along with tanespimycin in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (tanespimycin) | Trials (tanespimycin) | Recent Studies (post-2010) (tanespimycin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 921 | 39 | 496 |
| Protein | Taxonomy | lapatinib (IC50) | tanespimycin (IC50) |
|---|---|---|---|
| Corticotropin releasing hormone receptor 2 | Sus scrofa (pig) | 0.004 | |
| Lysine-specific demethylase 6B | Homo sapiens (human) | 0.4 | |
| Lysine-specific demethylase 4B | Homo sapiens (human) | 0.7 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 3 | |
| ATP-dependent molecular chaperone HSP82 | Saccharomyces cerevisiae S288C | 7.65 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.031 | |
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.9391 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.5124 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 3 | |
| Lysine-specific demethylase 5A | Homo sapiens (human) | 0.13 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.031 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.496 | |
| Putative heat shock protein HSP 90-alpha A4 | Homo sapiens (human) | 0.78 | |
| Lysine-specific demethylase 4C | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Chesebrough, J; Coats, S; Coffman, KT; Fazenbaker, CA; Gooya, J; Jackson, D; Jallal, B; Leow, CC; Weng, D | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T | 1 |
| Brouwers, AH; de Vries, EG; Lub-de Hooge, MN; Oude Munnink, TH; Schröder, CP; Timmer-Bosscha, H; Vedelaar, SR | 1 |
| Asantewaa, G; Ciesla, JH; Dewhurst, S; Harris, IS; Leach, J; Lutz, MM; Monaghan, M; Munger, J; Raymonda, MH; Schafer, XL; Smorodintsev-Schiller, LA; Takimoto, T | 1 |
1 review(s) available for lapatinib and tanespimycin
| Article | Year |
|---|---|
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
4 other study(ies) available for lapatinib and tanespimycin
| Article | Year |
|---|---|
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
OSU-03012 interacts with lapatinib to kill brain cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2012 |
Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Genes, erbB-1; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Immunoglobulin Fab Fragments; Lactams, Macrocyclic; Lapatinib; Male; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Benzoquinones; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Synergism; High-Throughput Screening Assays; Humans; Lactams, Macrocyclic; Lapatinib; Naphthalenes; Phenylurea Compounds; Pyrazoles; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |